ANO1 and head and neck squamous cell carcinoma: The overexpression of transmembrane member 16A (TMEM16A) leads to cisplatin resistance, and TRPML1 knockdown diminishes TMEM16A overexpression, resulting in sensitization to cisplatin treatment in head and neck squamous cell carcinoma cells [36,37].